Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H9Cl3N2OS |
Molecular Weight | 359.6595 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CSc1[nH]c2cc(c(cc2n1)Oc3cccc(c3Cl)Cl)Cl
InChI
InChIKey=NQPDXQQQCQDHHW-UHFFFAOYSA-N
InChI=1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19)
Molecular Formula | C14H9Cl3N2OS |
Molecular Weight | 359.6595 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26131614Curator's Comment:: description was created based on several sources, including
https://www.drugs.com/international/triclabendazole.html | https://www.drugs.com/mmx/triclabendazole.html | https://www.ncbi.nlm.nih.gov/pubmed/15259481 | https://www.ncbi.nlm.nih.gov/pubmed/26312936
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26131614
Curator's Comment:: description was created based on several sources, including
https://www.drugs.com/international/triclabendazole.html | https://www.drugs.com/mmx/triclabendazole.html | https://www.ncbi.nlm.nih.gov/pubmed/15259481 | https://www.ncbi.nlm.nih.gov/pubmed/26312936
Triclabendazole, (brand name Avomec, Egaten, etc) is a member of the benzimidazole family of anthelmintics used to treat liver flukes, specifically fascioliasis and paragonimiasis. Triclabendazole used routinely since 1983 in veterinary practice for the treatment of fascioliasis. It was not used in humans until the 1989 epidemic of fascioliasis near the Caspian Sea when Iranian authorities approved the use of the veterinary formulation to treat the infection. Fasciolicidal not only against the adult worms present in the biliary ducts, but also against the immature larval stages of Fasciola migrating through the hepatic parenchyma. Triclabendazole is shown to penetrate into liver flukes by transtegumentary absorption followed by inhibition of the parasite's motility, probably related to the destruction of the microtubular structure, resulting in the death of the parasite; the immobilizing effect is paralleled by changes in the parasite's resting tegumental membrane potential, strongly inhibiting the release of proteolytic enzymes, a process that appears critical to the survival of the parasite. Side effects are generally few, but can include abdominal pain and headaches. Biliary colic may occur due to dying worms. While no harms have been found with use during pregnancy, triclabendazole has not been well studied in this population. Triclabendazole is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is not commercially available in the United States.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3563 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20426472 |
15.0 µM [IC50] | ||
Target ID: CHEMBL613455 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20430484 |
|||
Target ID: CHEMBL612860 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25455496 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Egaten Approved UseUnknown |
|||
Curative | Egaten Approved UseUnknown |
|||
Curative | Egaten Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.34 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9663817/ |
10 mg/kg 1 times / day multiple, oral dose: 10 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
TRICLABENDAZOLE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.16 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9663817/ |
10 mg/kg 1 times / day multiple, oral dose: 10 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
TRICLABENDAZOLE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
1.16 μM |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TRICLABENDAZOLE plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.55 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9663817/ |
10 mg/kg 1 times / day multiple, oral dose: 10 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
TRICLABENDAZOLE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5.72 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9663817/ |
10 mg/kg 1 times / day multiple, oral dose: 10 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
TRICLABENDAZOLE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
5.72 μM × h |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TRICLABENDAZOLE plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8 h |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TRICLABENDAZOLE plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.3% |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TRICLABENDAZOLE plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg/kg 1 times / 8 hours multiple, oral (typical) Dose: 10 mg/kg, 1 times / 8 hours Route: oral Route: multiple Dose: 10 mg/kg, 1 times / 8 hours Sources: |
unhealthy, 12-60 years n = 47 Health Status: unhealthy Condition: Paragonimiasis Age Group: 12-60 years Sex: M+F Population Size: 47 Sources: |
Other AEs: Abdominal pain, Headache... Other AEs: Abdominal pain (6.4%) Sources: Headache (10.6%) Dizziness (4.3%) Jaundice (2.1%) |
10 mg/kg 1 times / 8 hours multiple, oral (typical) Dose: 10 mg/kg, 1 times / 8 hours Route: oral Route: multiple Dose: 10 mg/kg, 1 times / 8 hours Sources: |
unhealthy, 4-68 years n = 154 Health Status: unhealthy Condition: Paragonimiasis Age Group: 4-68 years Sex: M+F Population Size: 154 Sources: |
Other AEs: Dizziness, Abdominal pain... Other AEs: Dizziness (5.4%) Sources: Abdominal pain (1.3%) Diarrhea (1.3%) Fever (1.9%) |
10 mg/kg 1 times / 8 hours multiple, oral (typical) Dose: 10 mg/kg, 1 times / 8 hours Route: oral Route: multiple Dose: 10 mg/kg, 1 times / 8 hours Sources: |
unhealthy, 5-54 years n = 35 Health Status: unhealthy Condition: Paragonimiasis Age Group: 5-54 years Sex: M+F Population Size: 35 Sources: |
Other AEs: Headache, Abdominal pain... Other AEs: Headache (5.7%) Sources: Abdominal pain (5.7%) Vomiting (2.9%) Diarrhea (2.9%) |
10 mg/kg 1 times / day multiple, oral Recommended Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 82 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 82 Sources: |
Other AEs: Abdominal pain, Biliary colic... Other AEs: Abdominal pain (grade 3, 1.2%) Sources: Biliary colic (grade 1-2, 49%) Jaundice (grade 1-2, 7.2%) Epigastric pain (grade 1-2, 42.7%) Nausea (grade 1-2, 8.5%) Fever (grade 1-2, 8.5%) Pruritus (grade 1-2, 6.1%) Urticaria (grade 1-2, 2.4%) |
10 mg/kg 2 times / day multiple, oral Recommended Dose: 10 mg/kg, 2 times / day Route: oral Route: multiple Dose: 10 mg/kg, 2 times / day Sources: |
unhealthy, adult | children n = 28 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 28 Sources: |
Other AEs: Abdominal pain, Hyperhidrosis... Other AEs: Abdominal pain (93%) Sources: Hyperhidrosis (25%) Nausea (18%) Urticaria (11%) Vomiting (7%) Headache (14%) Pruritus (4%) Musculoskeletal chest pain (4%) Decreased appetite (18%) Diarrhea (7%) |
15 mg/kg single, oral (mean) Recommended Dose: 15 mg/kg Route: oral Route: single Dose: 15 mg/kg Sources: |
unhealthy, adult | children n = 214 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 214 Sources: |
Other AEs: Bilirubin increased, AST increased... Other AEs: Bilirubin increased (6.8%) Sources: AST increased (4.5%) Alkaline phosphatase increased (4.2%) ALT increased (3%) |
10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Other AEs: Abdominal pain, Hyperhidrosis... Other AEs: Abdominal pain (56%) Sources: Hyperhidrosis (23%) Vertigo (9%) Nausea (8%) Urticaria (7%) Vomiting (6%) Headache (6%) Dyspnea (5%) Pruritus (4%) Asthenia (4%) Musculoskeletal chest pain (4%) Cough (4%) Decreased appetite (3%) Chest pain (3%) Pyrexia (2%) Jaundice (2%) Chest discomfort (2%) Constipation (< 2%) Biliary colic (< 2%) Arthralgia (< 2%) Back pain (< 2%) Spinal pain (< 2%) Chromaturia (< 2%) |
10 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age 16.3 years n = 4 Health Status: unhealthy Condition: fascioliasis Age Group: mean age 16.3 years Sex: M+F Population Size: 4 Sources: |
Other AEs: Abdominal pain, Fatigue... Other AEs: Abdominal pain (grade 1, 100%) Sources: Fatigue (grade 1, 50%) Headache (grade 1-2, 75%) Diarrhea (grade 1, 25%) Nausea (grade 1, 75%) Vomiting (grade 1, 25%) Fever (grade 1-2, 25%) Dizziness (grade 1, 50%) |
10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age14.4 years n = 16 Health Status: unhealthy Condition: fascioliasis Age Group: mean age14.4 years Sex: M+F Population Size: 16 Sources: |
Other AEs: Abdominal pain, Fatigue... Other AEs: Abdominal pain (grade 1-2) Sources: Fatigue (grade 1) Headache (grade 1-2) Diarrhea (grade 1-2) Vomiting (grade 1) Fever (grade 1-2) Dizziness (grade 1) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Headache | 10.6% | 10 mg/kg 1 times / 8 hours multiple, oral (typical) Dose: 10 mg/kg, 1 times / 8 hours Route: oral Route: multiple Dose: 10 mg/kg, 1 times / 8 hours Sources: |
unhealthy, 12-60 years n = 47 Health Status: unhealthy Condition: Paragonimiasis Age Group: 12-60 years Sex: M+F Population Size: 47 Sources: |
Jaundice | 2.1% | 10 mg/kg 1 times / 8 hours multiple, oral (typical) Dose: 10 mg/kg, 1 times / 8 hours Route: oral Route: multiple Dose: 10 mg/kg, 1 times / 8 hours Sources: |
unhealthy, 12-60 years n = 47 Health Status: unhealthy Condition: Paragonimiasis Age Group: 12-60 years Sex: M+F Population Size: 47 Sources: |
Dizziness | 4.3% | 10 mg/kg 1 times / 8 hours multiple, oral (typical) Dose: 10 mg/kg, 1 times / 8 hours Route: oral Route: multiple Dose: 10 mg/kg, 1 times / 8 hours Sources: |
unhealthy, 12-60 years n = 47 Health Status: unhealthy Condition: Paragonimiasis Age Group: 12-60 years Sex: M+F Population Size: 47 Sources: |
Abdominal pain | 6.4% | 10 mg/kg 1 times / 8 hours multiple, oral (typical) Dose: 10 mg/kg, 1 times / 8 hours Route: oral Route: multiple Dose: 10 mg/kg, 1 times / 8 hours Sources: |
unhealthy, 12-60 years n = 47 Health Status: unhealthy Condition: Paragonimiasis Age Group: 12-60 years Sex: M+F Population Size: 47 Sources: |
Abdominal pain | 1.3% | 10 mg/kg 1 times / 8 hours multiple, oral (typical) Dose: 10 mg/kg, 1 times / 8 hours Route: oral Route: multiple Dose: 10 mg/kg, 1 times / 8 hours Sources: |
unhealthy, 4-68 years n = 154 Health Status: unhealthy Condition: Paragonimiasis Age Group: 4-68 years Sex: M+F Population Size: 154 Sources: |
Diarrhea | 1.3% | 10 mg/kg 1 times / 8 hours multiple, oral (typical) Dose: 10 mg/kg, 1 times / 8 hours Route: oral Route: multiple Dose: 10 mg/kg, 1 times / 8 hours Sources: |
unhealthy, 4-68 years n = 154 Health Status: unhealthy Condition: Paragonimiasis Age Group: 4-68 years Sex: M+F Population Size: 154 Sources: |
Fever | 1.9% | 10 mg/kg 1 times / 8 hours multiple, oral (typical) Dose: 10 mg/kg, 1 times / 8 hours Route: oral Route: multiple Dose: 10 mg/kg, 1 times / 8 hours Sources: |
unhealthy, 4-68 years n = 154 Health Status: unhealthy Condition: Paragonimiasis Age Group: 4-68 years Sex: M+F Population Size: 154 Sources: |
Dizziness | 5.4% | 10 mg/kg 1 times / 8 hours multiple, oral (typical) Dose: 10 mg/kg, 1 times / 8 hours Route: oral Route: multiple Dose: 10 mg/kg, 1 times / 8 hours Sources: |
unhealthy, 4-68 years n = 154 Health Status: unhealthy Condition: Paragonimiasis Age Group: 4-68 years Sex: M+F Population Size: 154 Sources: |
Diarrhea | 2.9% | 10 mg/kg 1 times / 8 hours multiple, oral (typical) Dose: 10 mg/kg, 1 times / 8 hours Route: oral Route: multiple Dose: 10 mg/kg, 1 times / 8 hours Sources: |
unhealthy, 5-54 years n = 35 Health Status: unhealthy Condition: Paragonimiasis Age Group: 5-54 years Sex: M+F Population Size: 35 Sources: |
Vomiting | 2.9% | 10 mg/kg 1 times / 8 hours multiple, oral (typical) Dose: 10 mg/kg, 1 times / 8 hours Route: oral Route: multiple Dose: 10 mg/kg, 1 times / 8 hours Sources: |
unhealthy, 5-54 years n = 35 Health Status: unhealthy Condition: Paragonimiasis Age Group: 5-54 years Sex: M+F Population Size: 35 Sources: |
Abdominal pain | 5.7% | 10 mg/kg 1 times / 8 hours multiple, oral (typical) Dose: 10 mg/kg, 1 times / 8 hours Route: oral Route: multiple Dose: 10 mg/kg, 1 times / 8 hours Sources: |
unhealthy, 5-54 years n = 35 Health Status: unhealthy Condition: Paragonimiasis Age Group: 5-54 years Sex: M+F Population Size: 35 Sources: |
Headache | 5.7% | 10 mg/kg 1 times / 8 hours multiple, oral (typical) Dose: 10 mg/kg, 1 times / 8 hours Route: oral Route: multiple Dose: 10 mg/kg, 1 times / 8 hours Sources: |
unhealthy, 5-54 years n = 35 Health Status: unhealthy Condition: Paragonimiasis Age Group: 5-54 years Sex: M+F Population Size: 35 Sources: |
Urticaria | grade 1-2, 2.4% | 10 mg/kg 1 times / day multiple, oral Recommended Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 82 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 82 Sources: |
Epigastric pain | grade 1-2, 42.7% | 10 mg/kg 1 times / day multiple, oral Recommended Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 82 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 82 Sources: |
Biliary colic | grade 1-2, 49% | 10 mg/kg 1 times / day multiple, oral Recommended Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 82 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 82 Sources: |
Pruritus | grade 1-2, 6.1% | 10 mg/kg 1 times / day multiple, oral Recommended Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 82 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 82 Sources: |
Jaundice | grade 1-2, 7.2% | 10 mg/kg 1 times / day multiple, oral Recommended Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 82 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 82 Sources: |
Fever | grade 1-2, 8.5% | 10 mg/kg 1 times / day multiple, oral Recommended Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 82 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 82 Sources: |
Nausea | grade 1-2, 8.5% | 10 mg/kg 1 times / day multiple, oral Recommended Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 82 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 82 Sources: |
Abdominal pain | grade 3, 1.2% | 10 mg/kg 1 times / day multiple, oral Recommended Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 82 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 82 Sources: |
Urticaria | 11% | 10 mg/kg 2 times / day multiple, oral Recommended Dose: 10 mg/kg, 2 times / day Route: oral Route: multiple Dose: 10 mg/kg, 2 times / day Sources: |
unhealthy, adult | children n = 28 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 28 Sources: |
Headache | 14% | 10 mg/kg 2 times / day multiple, oral Recommended Dose: 10 mg/kg, 2 times / day Route: oral Route: multiple Dose: 10 mg/kg, 2 times / day Sources: |
unhealthy, adult | children n = 28 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 28 Sources: |
Decreased appetite | 18% | 10 mg/kg 2 times / day multiple, oral Recommended Dose: 10 mg/kg, 2 times / day Route: oral Route: multiple Dose: 10 mg/kg, 2 times / day Sources: |
unhealthy, adult | children n = 28 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 28 Sources: |
Nausea | 18% | 10 mg/kg 2 times / day multiple, oral Recommended Dose: 10 mg/kg, 2 times / day Route: oral Route: multiple Dose: 10 mg/kg, 2 times / day Sources: |
unhealthy, adult | children n = 28 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 28 Sources: |
Hyperhidrosis | 25% | 10 mg/kg 2 times / day multiple, oral Recommended Dose: 10 mg/kg, 2 times / day Route: oral Route: multiple Dose: 10 mg/kg, 2 times / day Sources: |
unhealthy, adult | children n = 28 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 28 Sources: |
Musculoskeletal chest pain | 4% | 10 mg/kg 2 times / day multiple, oral Recommended Dose: 10 mg/kg, 2 times / day Route: oral Route: multiple Dose: 10 mg/kg, 2 times / day Sources: |
unhealthy, adult | children n = 28 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 28 Sources: |
Pruritus | 4% | 10 mg/kg 2 times / day multiple, oral Recommended Dose: 10 mg/kg, 2 times / day Route: oral Route: multiple Dose: 10 mg/kg, 2 times / day Sources: |
unhealthy, adult | children n = 28 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 28 Sources: |
Diarrhea | 7% | 10 mg/kg 2 times / day multiple, oral Recommended Dose: 10 mg/kg, 2 times / day Route: oral Route: multiple Dose: 10 mg/kg, 2 times / day Sources: |
unhealthy, adult | children n = 28 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 28 Sources: |
Vomiting | 7% | 10 mg/kg 2 times / day multiple, oral Recommended Dose: 10 mg/kg, 2 times / day Route: oral Route: multiple Dose: 10 mg/kg, 2 times / day Sources: |
unhealthy, adult | children n = 28 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 28 Sources: |
Abdominal pain | 93% | 10 mg/kg 2 times / day multiple, oral Recommended Dose: 10 mg/kg, 2 times / day Route: oral Route: multiple Dose: 10 mg/kg, 2 times / day Sources: |
unhealthy, adult | children n = 28 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 28 Sources: |
ALT increased | 3% | 15 mg/kg single, oral (mean) Recommended Dose: 15 mg/kg Route: oral Route: single Dose: 15 mg/kg Sources: |
unhealthy, adult | children n = 214 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 214 Sources: |
Alkaline phosphatase increased | 4.2% | 15 mg/kg single, oral (mean) Recommended Dose: 15 mg/kg Route: oral Route: single Dose: 15 mg/kg Sources: |
unhealthy, adult | children n = 214 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 214 Sources: |
AST increased | 4.5% | 15 mg/kg single, oral (mean) Recommended Dose: 15 mg/kg Route: oral Route: single Dose: 15 mg/kg Sources: |
unhealthy, adult | children n = 214 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 214 Sources: |
Bilirubin increased | 6.8% | 15 mg/kg single, oral (mean) Recommended Dose: 15 mg/kg Route: oral Route: single Dose: 15 mg/kg Sources: |
unhealthy, adult | children n = 214 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 214 Sources: |
Chest discomfort | 2% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Jaundice | 2% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Pyrexia | 2% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Hyperhidrosis | 23% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Chest pain | 3% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Decreased appetite | 3% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Asthenia | 4% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Cough | 4% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Musculoskeletal chest pain | 4% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Pruritus | 4% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Dyspnea | 5% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Abdominal pain | 56% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Headache | 6% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Vomiting | 6% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Urticaria | 7% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Nausea | 8% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Vertigo | 9% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Arthralgia | < 2% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Back pain | < 2% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Biliary colic | < 2% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Chromaturia | < 2% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Constipation | < 2% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Spinal pain | < 2% | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, adult | children n = 186 Health Status: unhealthy Condition: fascioliasis Age Group: adult | children Sex: M+F Population Size: 186 Sources: |
Abdominal pain | grade 1, 100% | 10 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age 16.3 years n = 4 Health Status: unhealthy Condition: fascioliasis Age Group: mean age 16.3 years Sex: M+F Population Size: 4 Sources: |
Diarrhea | grade 1, 25% | 10 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age 16.3 years n = 4 Health Status: unhealthy Condition: fascioliasis Age Group: mean age 16.3 years Sex: M+F Population Size: 4 Sources: |
Vomiting | grade 1, 25% | 10 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age 16.3 years n = 4 Health Status: unhealthy Condition: fascioliasis Age Group: mean age 16.3 years Sex: M+F Population Size: 4 Sources: |
Dizziness | grade 1, 50% | 10 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age 16.3 years n = 4 Health Status: unhealthy Condition: fascioliasis Age Group: mean age 16.3 years Sex: M+F Population Size: 4 Sources: |
Fatigue | grade 1, 50% | 10 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age 16.3 years n = 4 Health Status: unhealthy Condition: fascioliasis Age Group: mean age 16.3 years Sex: M+F Population Size: 4 Sources: |
Nausea | grade 1, 75% | 10 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age 16.3 years n = 4 Health Status: unhealthy Condition: fascioliasis Age Group: mean age 16.3 years Sex: M+F Population Size: 4 Sources: |
Fever | grade 1-2, 25% | 10 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age 16.3 years n = 4 Health Status: unhealthy Condition: fascioliasis Age Group: mean age 16.3 years Sex: M+F Population Size: 4 Sources: |
Headache | grade 1-2, 75% | 10 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age 16.3 years n = 4 Health Status: unhealthy Condition: fascioliasis Age Group: mean age 16.3 years Sex: M+F Population Size: 4 Sources: |
Dizziness | grade 1 | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age14.4 years n = 16 Health Status: unhealthy Condition: fascioliasis Age Group: mean age14.4 years Sex: M+F Population Size: 16 Sources: |
Fatigue | grade 1 | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age14.4 years n = 16 Health Status: unhealthy Condition: fascioliasis Age Group: mean age14.4 years Sex: M+F Population Size: 16 Sources: |
Vomiting | grade 1 | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age14.4 years n = 16 Health Status: unhealthy Condition: fascioliasis Age Group: mean age14.4 years Sex: M+F Population Size: 16 Sources: |
Abdominal pain | grade 1-2 | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age14.4 years n = 16 Health Status: unhealthy Condition: fascioliasis Age Group: mean age14.4 years Sex: M+F Population Size: 16 Sources: |
Diarrhea | grade 1-2 | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age14.4 years n = 16 Health Status: unhealthy Condition: fascioliasis Age Group: mean age14.4 years Sex: M+F Population Size: 16 Sources: |
Fever | grade 1-2 | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age14.4 years n = 16 Health Status: unhealthy Condition: fascioliasis Age Group: mean age14.4 years Sex: M+F Population Size: 16 Sources: |
Headache | grade 1-2 | 10 mg/kg 1 times / day single, oral Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
unhealthy, mean age14.4 years n = 16 Health Status: unhealthy Condition: fascioliasis Age Group: mean age14.4 years Sex: M+F Population Size: 16 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
yes [Ki 0.009 uM] | ||||
yes [Ki 0.016 uM] | ||||
yes [Ki 0.018 uM] | ||||
yes [Ki 0.05 uM] | ||||
yes [Ki 0.053 uM] | ||||
yes [Ki 0.061 uM] | ||||
yes [Ki 0.149 uM] | ||||
yes [Ki 0.166 uM] | ||||
yes [Ki 0.22 uM] | ||||
yes [Ki 0.37 uM] | ||||
yes [Ki 0.57 uM] | ||||
yes [Ki 0.75 uM] | ||||
yes [Ki 1.03 uM] | ||||
yes [Ki 1.27 uM] | ||||
yes [Ki 1.81 uM] | ||||
yes [Ki 12.5 uM] | ||||
yes [Ki 13 uM] | ||||
yes [Ki 2.31 uM] | ||||
yes [Ki 2.77 uM] | ||||
yes [Ki 4.32 uM] | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Experimental infection of rabbits with Fasciola gigantica and treatment with triclabendazole (TCBZ) or BT6: parasitological, haematological and immunological findings. | 2001 |
|
[A clinical trial of triclabendazole in the treatment of human paragonimiasis skrjabini]. | 2001 |
|
Efficacy of combined chemotherapy against gastrointestinal nematodes and Fasciola hepatica in cattle. | 2001 Aug 20 |
|
An experimental study on triclabendazole resistance of Fasciola hepatica in sheep. | 2001 Feb |
|
A comparative study on the effect of praziquantel and triclabendazole on Vampirolepis nana in vitro. | 2002 Apr |
|
[Chilhood hepatic fascioliasis treated with triclabendazol]. | 2002 Aug |
|
Pathological and immunohistochemical study of the liver and hepatic lymph nodes of sheep chronically reinfected with Fasciola hepatica, with or without triclabendazole treatment. | 2002 Jul |
|
A praziquantel-ineffective fascioliasis case successfully treated with triclabendazole. | 2002 Jun |
|
Antioxidant capacity in Fasciola hepatica patients before and after treatment with triclabendazole alone or in combination with ascorbic acid (vitamin C) and tocofersolan (vitamin E). | 2003 |
|
Pediatric fascioliasis: report of three cases. | 2003 Jan-Mar |
|
Comparison of two single-day regimens of triclabendazole for the treatment of human pulmonary paragonimiasis. | 2003 Jul-Aug |
|
The effect of the microtubule inhibitor tubulozole-C on the tegument of triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. | 2003 Sep |
|
Chemotherapy for major food-borne trematodes: a review. | 2004 Aug |
|
Liver, spleen, pancreas and kidney involvement by human fascioliasis: imaging findings. | 2004 Aug 4 |
|
Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro. | 2004 Dec |
|
Comparative assessment of the access of albendazole, fenbendazole and triclabendazole to Fasciola hepatica: effect of bile in the incubation medium. | 2004 Jan |
|
Human fascioliasis. | 2004 May |
|
Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis. | 2004 Nov |
|
[Human infection with Dicrocoelium dendriticum]. | 2004 Nov 19 |
|
Triclabendazole biotransformation and comparative diffusion of the parent drug and its oxidized metabolites into Fasciola hepatica. | 2004 Nov-Dec |
|
Measurement of triclabendazole and its metabolites in liver flukes: method development and full validation. | 2004 Sep 3 |
|
Monitoring and treatment of Fascioloides magna in semi-farm red deer husbandry in Croatia. | 2005 Aug |
|
Phenotype of hepatic infiltrates and hepatic lymph nodes of lambs primarily and challenge infected with Fasciola hepatica, with and without triclabendazole treatment. | 2005 Jan-Feb |
|
[Four cases of hepatic fascioliasis mimicking cholangiocarcinoma]. | 2005 Jun |
|
[Obstructive jaundice, Fasciola hepatica: a new case report]. | 2005 May-Aug |
|
Infection with Fasciola hepatica. | 2005 Nov |
|
Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes. | 2005 Oct |
|
Triclabendazole: new skills to unravel an old(ish) enigma. | 2005 Sep |
|
[Therapeutic alternatives in case of failure of first-line treatment of intestinal helminthiasis in adults]. | 2006 Aug |
|
Triclabendazole and its two main metabolites lack activity against Schistosoma mansoni in the mouse model. | 2006 Aug |
|
Adult triclabendazole-resistant Fasciola hepatica: surface and subsurface tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha. | 2006 Aug |
|
Stage-specific differences in fecundity over the life-cycle of two characterized isolates of the liver fluke, Fasciola hepatica. | 2006 Aug |
|
Response from Savioli and colleagues from the Department of Neglected Tropical Diseases, World Health Organization. | 2006 Jun |
|
Assessment of the main metabolism pathways for the flukicidal compound triclabendazole in sheep. | 2006 Jun |
|
Fasciola hepatica infection: clinical and computerized tomographic findings of ten patients. | 2006 Mar |
|
Systemic vasculitis associated with Fasciola hepatica infection. | 2006 Mar-Apr |
|
[Hepatobiliary fasciolasis without eosinophilia]. | 2006 Oct |
|
Fasciola hepatica: morphological effects of a combination of triclabendazole and clorsulon against mature fluke. | 2006 Oct |
|
Resistance of Fasciola hepatica to triclabendazole and albendazole in sheep in Spain. | 2006 Sep 23 |
|
Surgery in Fasciola hepatica pancreatitis: report of a case and review of literature. | 2007 Apr |
|
Activity of artemether and OZ78 against triclabendazole-resistant Fasciola hepatica. | 2007 Dec |
|
Immature triclabendazole-resistant Fasciola hepatica: tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha. | 2007 Jan |
|
An in vitro effect of propolis on adult worms of Fasciola gigantica. | 2007 Mar 31 |
|
[Fascioliasis: a 23-year retrospective study]. | 2007 Nov |
|
Fasciola hepatica: the infectivity of cattle-origin miracidia had increased over the past years in central France. | 2007 Sep |
|
A field trial of production and financial consequences of helminthosis control in sheep production in Ethiopia. | 2008 Apr 17 |
|
Natural history, clinicoradiologic correlates, and response to triclabendazole in acute massive fascioliasis. | 2008 Feb |
|
Use of triclabendazole for treatment of patients co-infected by Fasciola spp. and S. mansoni in Behera Governorate, Egypt. | 2008 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/mmx/triclabendazole.html
10 mg per kg of body weight as a single dose
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25455496
Triclabendazole was tested in vitro against recently excysted metacercariae. Triclabendazole was evaluated at concentrations of 10 and 50 mg/L., Triclabendazole demonstrated a fasciolicidal efficacy of 100% at a concentration of 10 and 50 mg/L at 24, 48 h and 72 hours post-treatment
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 22:13:15 UTC 2021
by
admin
on
Fri Jun 25 22:13:15 UTC 2021
|
Record UNII |
4784C8E03O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QP52AC01
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
||
|
WHO-ATC |
P02BX04
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
||
|
FDA ORPHAN DRUG |
564216
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.1.3
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
||
|
NCI_THESAURUS |
C250
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
||
|
FDA ORPHAN DRUG |
525416
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
68786-66-3
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
PRIMARY | |||
|
SUB11267MIG
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
PRIMARY | |||
|
C75236
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
PRIMARY | |||
|
M11087
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
PRIMARY | Merck Index | ||
|
C039276
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
PRIMARY | |||
|
2734
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
PRIMARY | |||
|
68786-66-3
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
PRIMARY | |||
|
2118525
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
PRIMARY | |||
|
Triclabendazole
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
PRIMARY | |||
|
4784C8E03O
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
PRIMARY | |||
|
DB12245
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
PRIMARY | |||
|
CHEMBL1086440
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
PRIMARY | |||
|
50248
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
PRIMARY | |||
|
5003
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
PRIMARY | |||
|
TRICLABENDAZOLE
Created by
admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET ORGANISM->INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET ORGANISM->INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
FOR VETERINARY USE
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
FOR VETERINARY USE
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
FOR VETERINARY USE
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||
Biological Half-life | PHARMACOKINETIC |
|
|
|||